Oct 22, 2026 08:45AM
Oct 7, 2026 08:33AM
Oct 7, 2026 08:30AM
Sep 2, 2026 08:30AM
Aug 21, 2026 08:30AM
Aug 21, 2026 08:30AM
Aug 12, 2026 05:13PM RenovoRx, Inc. (RNXT) Tops Q2 EPS by 2c
Aug 12, 2026 04:05PM
Aug 6, 2026 08:31AM
Aug 6, 2026 08:30AM
Aug 4, 2026 08:30AM
Jul 29, 2026 08:30AM
May 14, 2026 05:21PM
May 14, 2026 04:05PM RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter
Apr 29, 2026 08:30AM
Mar 30, 2026 04:05PM
Mar 20, 2026 08:30AM
Dec 1, 2025 08:30AM
Nov 19, 2025 08:30AM
Nov 13, 2025 05:52PM
Nov 13, 2025 04:05PM RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update
Oct 27, 2025 08:30AM
Aug 14, 2025 05:03PM
Aug 14, 2025 04:05PM
Jul 14, 2025 08:30AM
May 15, 2025 05:54PM
May 15, 2025 04:05PM
May 1, 2025 08:30AM RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET
Apr 1, 2025 08:30AM
Apr 1, 2025 08:30AM
Nov 14, 2024 08:00AM
Dec 21, 2023 08:30AM
Dec 19, 2023 08:30AM
Dec 13, 2023 08:31AM
Dec 13, 2023 08:31AM RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
Nov 16, 2023 08:35AM
Nov 16, 2023 08:35AM
Nov 14, 2023 08:30AM
Aug 17, 2023 08:30AM
Jun 29, 2023 08:03AM
Jun 29, 2023 08:00AM
Jun 1, 2023 08:30AM RenovoRx Initiates Patient Enrollment at University of Texas Southwestern Medical Center for Pivotal Phase III TIGeR-PaC Clinical Trial
May 25, 2023 08:30AM
May 15, 2023 08:30AM
Apr 14, 2023 08:30AM
Apr 14, 2023 08:30AM
Apr 11, 2023 08:30AM
Mar 30, 2023 08:30AM
Mar 30, 2023 08:30AM  RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy
Mar 8, 2023 08:32AM

1,233,143 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All